Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin in Cirrhotic Subjects With Chronic Genotype 1 HCV Infection

NCT01965535 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

155

Enrollment

INDUSTRY

Sponsor class

Conditions

HCV Infection

Interventions

DRUG: LDV/SOF
DRUG: RBV
DRUG: Placebo to match LDV/SOF
DRUG: Placebo to match RBV

Sponsor

Gilead Sciences